RheoScan received approval from Korea Food & Drug Administration(KFDA) though GMP tests as a First class medical device in Dec., 2005. Furthermore, RheoScan have declared CE for high quality manufacturing and management.
RheoScan formed key partnerships with leading research and medical institutions such as Korea University Hospital-Artificial Organ Research Center, Kyungpook National University Hospital, and has scheduled a number of clinical studies through to further validate the relationship between the biophysical properties of cell deformability and circulatory disorders.